ArticleRegenerative therapy2026
Hypoxia-preconditioned bone marrow mesenchymal stem cell-derived exosomes ameliorate knee osteoarthritis by promoting cartilage regeneration and alleviating pain in rats.
Article in Regenerative therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Research progress of mesenchymal stem cells/stromal cells and their derivatives against cell senescence in the treatment of osteoarthritis.Annals of medicine · 2026Review
- Recent advances in the use of stem cell-derived exosomes for joint regeneration.Molecular biology reports · 2026Review
- Mesenchymal stromal cells therapy for remodeling the joint microenvironment: mechanisms, nanotechnology-enhanced strategies, and translation prospects.Stem cell research & therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Knee osteoarthritis (KOA) is the most prevalent subtype of arthritis, characterized by progressive degeneration of articular cartilage. The present study aimed to investigate the reparative potential of exosomes derived from hypoxia-preconditioned bone marrow mesenchymal stem cells (Hypo-BMSCs-Exos) in treating cartilage damage associated with KOA. Methods: An in vitro KOA chondrocyte model was established through induction with interleukin-1β (IL-1β). Subsequently, the modeled chondrocytes were co-cultured with Hypo-BMSCs-Exos. Flow cytometry, Western blotting, immunofluorescence staining, and senescence-associated β-galactosidase (SA-β-gal) staining were used to evaluate the effects of Hypo-BMSCs-Exos on chondrocyte proliferation, apoptosis, extracellular matrix (ECM) metabolic homeostasis, and cellular senescence. For in vivo assessment of Hypo-BMSCs-Exos efficacy, exosomes were administered to KOA model rats via intra-articular injection. Histological scoring, Micro-CT, pain behavioral assessments, and immunohistochemical analysis were then performed to determine the reparative effects of Hypo-BMSCs-Exos on cartilage damage. Results: Hypo-BMSCs-Exos exerted superior effects in suppressing inflammatory responses, apoptosis, ECM degradation, and cellular senescence in rat chondrocytes. Specifically, treatment with Hypo-BMSCs-Exos upregulated the expression of ECM synthesis-related proteins (Collagen II, aggrecan) while downregulating the expression of ECM degradation-related proteins (ADAMTS-5, MMP-13), pro-inflammatory cytokines (iNOS, COX2), and key senescence-associated proteins (p53, p21, p16). Additionally, a reduction in the number of SA-β-gal-positive senescent chondrocytes was observed. In vivo experiments revealed that intra-articular injection of Hypo-BMSCs-Exos in KOA rats significantly improved the inflammatory microenvironment within the joint, promoted articular cartilage regeneration, and restored the structural integrity of subchondral bone. Furthermore, in vivo findings demonstrated that Hypo-BMSCs-Exos significantly regulated the expression of pain-related molecules and exerted a marked inhibitory effect on pain-related behaviors in KOA rats. Conclusion: Hypo-BMSCs-Exos can effectively alleviate cartilage degeneration and pain in KOA, thus offering a novel and promising cell-free therapeutic strategy for the intervention of KOA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.